Latest Industry Articles

Masimo Radical-7® with PVi®, SpHb®, and RD rainbow SET™  Masimo  (NASDAQ: MASI) has announced the findings of a recently published study in which researchers at Kocaeli University in Turkey compared the performance of conventional fluid management (CFM) to goal-di

This rescue  helicopter  provides emergency services to a New Zealand island with the help of a portable ultrasound Scattered across 150,000 square kilometers of beautiful farm land, mountainous terrain, and rugged coastline, South Island is the larger of New Zealand’s two maj

  Masimo  (NASDAQ: MASI) has announced the worldwide release of the Vital Signs Check Application, an integrated patient data collection and workflow application for the Masimo Root® patient monitoring and connectivity platform. Vital Signs Check, available for new and existing Root c

  Masimo  and Thermomedics, a  PositiveID  company, has announced the debut and U.S. market release of TIR-1™, a non-contact Bluetooth®-enabled thermometer that integrates seamlessly with the Masimo Root® patient monitoring and connectivity platform. TIR-1 is an easy-to-u

Masimo  has announced  the findings of an abstract presented at Euroanaesthesia 2018 in which researchers compared Masimo noninvasive and continuous hemoglobin (SpHb®) to intermittent and invasive lab hemoglobin (LabHb) in reflecting iatrogenic hemodilution during incremental

The Utah State Legislature and Governor Gary Herbert have recently signed into law the Concurrent Resolution on Deaths From Opioid-Induced Postoperative Respiratory Depression (SCR4). The resolution urges hospitals, clinicians, and researchers to examine and identify possible li

… Antimicrobial Susceptibility Testing (AST) times reduced from days to hours….   Hampshire Hospitals NHS Foundation Trust (HHFT) is pioneering the use of the Accelerate Pheno TM system from Accelerate Diagnostics, Inc., (Accelerate Diagnostics) a leading in vitro diagnostics company, t

In positive blood cultures, the Accelerate Pheno TM system identifies the agent causing the infection in 90 minutes and around 5 hours afterwards it provides information on the antibiotic sensitivity of the pathogen, which is 28 hours less than the current conventional system used in the La Pri

Masimo  (NASDAQ: MASI) has announced the use of Masimo technologies – O3® regional oximetry and SedLine® brain function monitoring – in two abstracts presented at the 2018 Annual Meeting of the International Anesthesia Research Society(IARS). Both studies investigated

Masimo announced today the findings of an abstract presented at the 2018 Annual Meeting of the Network for the Advancement of Patient Blood Management, Haemostatis and Thrombosis (NATA), in which researchers investigated the utility of Masimo noninvasive and continuous hemoglobin (SpHb®) in support